NELL2 as a potential marker of outcome in the cerebrospinal fluid of patients with tuberculous meningitis: preliminary results from a single-center observational study

Jianhua Chen, Jie Wu, Yong Luo, Nanqu HuangEuropean 2022 · DOI

Abstract

NELL2 in the CSF of TBM patients decreased significantly. Anti-tuberculosis treatment can improve the level of NELL2, which may become one of the potential markers of outcome in the cerebrospinal fluid of patients with tuberculous meningitis.

Introduction

Tuberculous meningitis (TBM) is a devastating infection of the membranes surrounding the brain and spinal cord. As the most lethal form of tuberculosis, it frequently results in permanent neurological damage for survivors. A significant clinical challenge lies in monitoring patient recovery; standard cerebrospinal fluid (CSF) tests—such as glucose, protein, and white blood cell counts—often lack the specificity to accurately reflect the state of neural tissue repair.

Researchers have identified that levels of the protein NELL2 (Nel-like 2) in the CSF significantly drop during the peak of TBM infection but rebound during successful anti-tuberculosis treatment. These findings suggest that NELL2 could serve as a valuable dynamic biomarker to monitor neurological recovery and treatment efficacy in real-time.

Methods and Cohort Selection

The authors conducted a single-center observational study at the First People’s Hospital of Zunyi, China, between 2017 and 2021. The study focused on quantifying NELL2 levels using Western Blotting (WB) and tracking changes over the course of treatment.

Participant flowchart illustrating the diagnostic pathway and cohort selection for the study.

As illustrated in the participant flowchart (Figure 1), the researchers screened 131 patients presenting with symptoms such as headache, fever, and abnormal mental behavior. The final study groups included:

  • TBM Group: 11 confirmed cases (verified via symptoms, CSF biochemistry, and Mycobacterium tuberculosis DNA testing).
  • Control Group: 18 patients with neurological symptoms but normal CSF findings and no infection.
  • Longitudinal Subgroup: 4 TBM patients who underwent repeated lumbar punctures at 0, 3, 7, 11, and 16 days post-treatment to observe dynamic protein changes.

NELL2 is a neuron-specific protein primarily expressed in the hippocampus and cerebral cortex. Because it is involved in neuronal proliferation and differentiation, its concentration in the CSF is believed to reflect the biological health and regenerative status of the central nervous system.

Key Results and Insights

The study's most significant finding is that NELL2 is a dynamic indicator of neural health rather than a static diagnostic marker.

At baseline, NELL2 levels in the TBM group were significantly lower than those in the control group ($t = -26.23, P < 0.01$). However, as patients responded to medication, a statistically significant upward trend emerged. NELL2 levels began to rise significantly as early as 7 days into treatment ($P < 0.05$). By day 16, levels were significantly higher than they were at days 3 and 7, mirroring the clinical improvements observed in the patients.

Sensitivity to Treatment

While traditional markers like chloride and protein showed trends toward normalization, the rise in NELL2 specifically pointed toward the restoration of the neuronal environment. This suggests that NELL2 may be a more sensitive indicator of recovery than traditional biochemical markers.

Limitations and Future Directions

The authors acknowledge several limitations to these preliminary results:

  • Small Sample Size: With only 11 TBM patients and 4 in the longitudinal follow-up, the statistical power is limited, necessitating larger multi-center validation studies.
  • Invasive Sampling: The requirement for repeated lumbar punctures led to a high dropout rate as patients improved and refused further procedures.
  • Short Follow-up Window: The 16-day observation period is short for a disease requiring months of therapy. Future research should track NELL2 levels over several months to see if they eventually return to normal control levels.
  • Specificity: Further comparison against other types of meningitis (viral or fungal) is needed to determine if this NELL2 "rebound" is unique to tuberculosis recovery.

Summary updated

Abstract

NELL2 in the CSF of TBM patients decreased significantly. Anti-tuberculosis treatment can improve the level of NELL2, which may become one of the potential markers of outcome in the cerebrospinal fluid of patients with tuberculous meningitis.
BibTeX
@inproceedings{chen2022nell,
  author = {Jianhua Chen and Jie Wu and Yong Luo and Nanqu Huang},
  title = {{NELL2 as a potential marker of outcome in the cerebrospinal fluid of patients with tuberculous meningitis: preliminary results from a single-center observational study}},
  booktitle = {European},
  year = {2022},
  doi = {10.1186/s40001-022-00921-7},
}
Figure